V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20117132 | 20180160 | 1.76 | 78.4 | Curative (C) | 2018-07-10 | 2018-07-17 | null | 01 | Y | BEVACIZUMAB | 101176873 |
| 20117727 | 20180161 | 1.53 | 83 | Palliative (P) | 2020-12-17 | 2021-01-07 | null | 02 | N | CARBOPLATIN + PACLITAXEL + RT | 100676526 |
| 20121424 | 20180162 | 1.73 | 74.8 | null | 2020-06-16 | 2020-06-16 | null | 2 | null | PEMBROLIZUMAB | 100191559 |
| 20121799 | 20180163 | 1.73 | 76.8 | Disease modification (D) | 2021-01-04 | 2021-01-10 | null | 02 | N | MITOMYCIN INTRAVESICULAR | 101838727 |
| 20124005 | 20180165 | 1.65 | null | 03 | 2020-08-24 | 2021-02-20 | null | 2 | N | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 101570061 |
| 20124470 | 20180166 | 0 | 64.4 | null | 2021-04-04 | 2021-04-13 | null | 02 | null | CISPLATIN + ETOPOSIDE | 100368605 |
| 20127387 | 20180167 | 1.55 | null | Palliative (P) | 2020-10-19 | 2020-11-05 | null | 02 | null | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 100568877 |
| 20128425 | 20180168 | 0 | 54.6 | Palliative (P) | 2021-02-23 | 2021-02-23 | null | 2 | N | LENALIDOMIDE | 101186030 |
| 20128758 | 20180169 | 1.63 | 57 | Neo-adjuvant (N) | 2022-03-06 | 2022-03-06 | null | N | Y | ATEZOLIZUMAB + BEVACIZUMAB | 100056430 |
| 20130428 | 20180170 | 1.9 | null | null | 2022-02-10 | 2022-02-12 | null | 02 | null | SUNITINIB | 100859039 |
| 20131694 | 20180171 | null | 79.7 | Curative (C) | 2021-01-03 | 2021-09-29 | null | N | N | CETUXIMAB + ENCORAFENIB | 101227084 |
| 20131904 | 20180172 | 1.7 | 89.8 | Palliative (P) | 2021-11-24 | 2021-11-28 | null | 02 | N | SCALOP-2 TRIAL | 100112547 |
| 20131959 | 20180173 | null | null | null | 2018-02-19 | 2019-06-24 | null | 02 | null | OXALIPLATIN | 101090541 |
| 20133526 | 20180174 | 1.69 | 90 | null | 2021-03-04 | 2021-04-07 | null | 02 | null | SCALOP-2 TRIAL | 101369305 |
| 20134721 | 20180175 | 1.83 | 110 | Palliative (P) | 2019-07-11 | 2019-08-01 | null | 02 | N | OCTREOTIDE | 100284389 |
| 20141745 | 20180176 | 1.91 | 85.5 | Palliative (P) | 2019-12-13 | 2019-12-17 | null | 02 | Y | CAPECITABINE + CISPLATIN + EPIRUBICIN | 101465889 |
| 20143244 | 20180178 | 1.7 | 95.91 | null | 2016-05-16 | 2019-06-21 | null | 02 | null | CISPLATIN + EPIRUBICIN + FLUOROURACIL | 100190619 |
| 20143370 | 20180179 | 1.78 | 67.8 | Neo-adjuvant (N) | 2017-01-31 | 2017-01-31 | null | 02 | Y | OCTREOTIDE | 100028118 |
| 20143988 | 20180180 | 1.5 | null | Curative (C) | null | 2019-12-01 | Bevacizumab + Irinotecan + MdG | 02 | null | ERIBULIN | 101187221 |
| 20148182 | 20180181 | 1.57 | 62.2 | Palliative (P) | 2020-01-17 | 2020-01-28 | Capecitabine+Cisplatin+Streptozocin | N | N | INTERAACT TRIAL | 101627462 |
| 20148558 | 20180182 | 1.58 | 63.6 | Curative (C) | null | 2021-06-26 | ACTICCA-1 Trial | null | N | AFATINIB | 101213518 |
| 20152042 | 20180184 | 1.63 | 48 | 03 | 2017-06-23 | 2019-04-14 | ESHAP | N | Y | NAB-PACLITAXEL | 100555245 |
| 20154024 | 20180185 | 1.56 | 75.1 | null | 2020-01-14 | 2020-05-13 | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | null | null | CARBOPLATIN + PEMETREXED | 101388079 |
| 20155475 | 20180186 | 1.61 | 68 | null | 2021-01-25 | 2021-08-24 | CAP + RT | 01 | null | CABAZITAXEL | 101204404 |
| 20157177 | 20180187 | null | null | Curative (C) | 2022-05-05 | 2022-05-18 | CISPLATIN + FLUOROURACIL + RT | N | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101243634 |
| 20157596 | 20180188 | 1.47 | 81.2 | Palliative (P) | 2018-03-13 | 2018-03-13 | CAPECITABINE + IRINOTECAN + Panitumumab | N | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100080821 |
| 20159094 | 20180189 | 1.74 | 71.9 | Palliative (P) | 2021-08-13 | 2022-03-25 | ATEZOLIZUMAB + CARBOPLATIN + ETOPOSIDE | 02 | N | CISPLATIN + FU + TRASTUZUMAB | 101121232 |
| 20159370 | 20180190 | 1.89 | 77 | null | 2021-10-13 | 2021-10-13 | Bevacizumab + Irinotecan + MdG | 02 | N | CAPECITABINE + DOCETAXEL | 101429125 |
| 20169180 | 20180192 | 1.72 | 0 | Adjuvant (A) | 2017-12-24 | 2018-03-18 | FOXTROT TRIAL | 02 | N | BENDAMUSTINE + POLATUZUMAB VEDOTIN + RITUXIMAB | 100813839 |
| 20172887 | 20180194 | null | null | null | 2021-11-21 | 2021-12-04 | CHOP R - 21 days | 02 | null | CHLORAMBUCIL | 101667430 |
| 20180926 | 20180196 | 1.65 | 47.6 | null | 2020-01-10 | 2020-01-12 | Ripretinib | 02 | N | CAPECITABINE + STREPTOZOCIN | 100350853 |
| 20184308 | 20180199 | 1.9 | 76.7 | Neo-adjuvant (N) | 2021-11-26 | 2022-04-04 | Letrozole + Palbociclib | N | N | AZACITIDINE | 100669532 |
| 20184820 | 20180200 | 1.86 | 65 | Adjuvant (A) | 2016-08-31 | 2016-09-01 | MITOMYCIN | 02 | N | PHITT | 100129984 |
| 20186389 | 20180201 | 1.89 | 56.8 | 03 | 2020-06-07 | 2020-06-23 | Gemcitabine + Paclitaxel | 02 | N | CARBOPLATIN + RALTITREXED | 101404371 |
| 20191722 | 20180202 | 1.8 | 60.8 | null | 2019-09-24 | 2019-09-25 | EEF or EOF | 02 | null | CAPE + OXALIPLATIN + TRASTUZUMAB | 100789396 |
| 20193816 | 20180204 | 1.56 | 85.3 | Palliative (P) | 2020-01-02 | 2020-01-17 | CISPLATIN + FLUOROURACIL + RT | 02 | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 100567206 |
| 20194172 | 20180205 | 1.51 | 80.3 | Neo-adjuvant (N) | 2017-09-28 | 2018-02-14 | Hydroxycarbamide | 02 | N | TOPOTECAN | 100352389 |
| 20194533 | 20180206 | 1.61 | 106 | null | 2018-01-22 | 2018-02-13 | SCOPE 2 TRIAL | N | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100062470 |
| 20197298 | 20180207 | 0.9 | 88.7 | Palliative (P) | 2021-10-14 | 2021-11-20 | Bendamustine+Rituximab(Sub Courses) | 02 | null | BEVACIZUMAB + FLUOROURACIL + IRINOTECAN | 101227674 |
| 20197694 | 20180208 | 1.69 | 59.2 | Palliative (P) | 2020-03-09 | 2020-06-26 | Cisplatin +FU +Trastuzumab - Maint | 02 | N | PHITT | 100150951 |
| 20198192 | 20180209 | 1.59 | 67.5 | Adjuvant (A) | 2019-11-28 | 2019-11-30 | null | 02 | N | ETOPOSIDE | 100980667 |
| 20199648 | 20180210 | null | null | Neo-adjuvant (N) | 2021-08-04 | 2021-09-24 | Temozolomide 200mg/m2 | 02 | null | EPIRUBICIN | 100122884 |
| 20200823 | 20180211 | 1.75 | 66 | Neo-adjuvant (N) | 2019-01-02 | 2019-01-02 | IDELALISIB + RITUXIMAB | N | null | SCOPE 1 TRIAL | 100337471 |
| 20201166 | 20180212 | 1.81 | 48.2 | null | 2019-06-18 | 2019-06-18 | AFATINIB | 02 | null | CARBOPLATIN + VINORELBINE | 100687744 |
| 20201314 | 20180213 | 1.81 | 0 | Palliative (P) | 2018-11-01 | 2018-12-04 | Hydroxycarbamide | 02 | N | BACILLUS CALMETTE-GUERIN | 101256435 |
| 20206048 | 20180218 | 1.51 | 74.4 | Disease modification (D) | null | 2020-01-27 | DOCETAXEL + PERTUZUMAB + TRASTUZUMAB | N | null | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101257517 |
| 20206119 | 20180219 | 1.75 | 25.5 | 03 | 2018-01-16 | 2018-02-13 | Gemcitabine + RT pancreas | 02 | N | DOXORUBICIN | 100637538 |
| 20206443 | 20180220 | 1.69 | null | Palliative (P) | 2018-11-27 | 2019-01-22 | BCG Intravesical | 02 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 101450822 |
| 20206480 | 20180221 | 1.61 | 80.3 | Palliative (P) | 2018-09-23 | 2018-10-06 | Capecitabine + Trastuzumab | 02 | N | OLARATUMAB | 100364677 |
| 20206530 | 20180222 | 1.6 | 55 | Neo-adjuvant (N) | 2019-09-11 | 2019-09-16 | CHOP R - 21 days | 02 | N | DARATUMUMAB | 101395576 |